The mammalian target of rapamycin (mTOR) signaling cascade is a key regulatory pathway controlling initiation of messenger RNA in mammalian cells. Although dysregulation of mTOR signaling has been reported earlier in cancers, there is paucity of data about mTOR expression in papillary thyroid carcinoma (PTC). Therefore, in this study, we investigated the presence of mTORC2 and mTORC1 complexes in a large cohort of >500 PTC samples. Our clinical data showed the presence of active mTORC1 and mTORC2 in 81 and 39% of PTC samples, respectively. Interestingly, coexpression of mTORC1 and mTORC2 activity was seen in a 32.5% (164/504) of the PTC studied and this association was statistically significant (P = 0.0244). mTOR signaling complex was also found to be associated with activated AKT and 4E-BP1. In vitro, using Torin2, a second-generation mTOR inhibitor or gene silencing of mTOR expression prevented mTORC1 and mTORC2 activity leading to inactivation of P70S6, 4E-BP1, AKT and Bad. Inhibition of mTOR activity led to downregulation of cyclin D1, a gene regulated by messenger RNA translation via phosphorylation of 4E-BP1. Torin2 treatment also inhibited cell viability and induced caspase-dependent apoptosis via activation of mitochondrial apoptotic pathway in PTC cells. Finally, Torin2 treatment induces anticancer effect on PTC xenograft tumor growth in nude mice via inhibition of mTORC1 and mTORC2 and its associated pathways. Our results suggest that coexpression of mTORC1 and mTORC2 is seen frequently in the clinical PTC samples and dual targeting of mTORC1 and mTORC2 activity may be an attractive therapeutic target for treatment of PTC.
Introduction
Thyroid cancer is the most common endocrine malignancy, accounting for 3% of all cancers worldwide (1) . Papillary thyroid carcinoma (PTC) is the most common histology subtype and accounts for >75% of all thyroid cancer (2-4). Interestingly, the incidence of PTC is increasing worldwide (1, 5) . Even though, PTC is a treatable cancer where the 10 year survival rate has reached almost 90% with surgery and radioactive iodine treatment, there are cases of PTC that remain refractory to treatment (6) . In these 10-15% of cases, recurrence occurs in local/regional and distant sites and these recurrences are usually non-responsiveness to radio-ablation therapy (7) . Because of the resistance to the current treatment, new approaches for the management of resistant PTC are being evaluated and therefore molecular-targeted therapy is gaining importance for the management of PTC (8, 9) .
Mammalian target of rapamycin (mTOR) is a serine-threonine kinase belonging to the PI3-kinase family of proteins that controls cell survival and growth by regulating various cellular process including protein synthesis and autophagy (10, 11) . mTOR is known to be an important component of two different protein complexes mTORC1 and mTORC2 (12) . The mTOR-containing complexes have different sensitivities to rapamycin as well as upstream inputs and downstream outputs (13) . Functionality of mTORC1 complex is dependent upon activation of S6K1 and 4E-BP1 that leads to translation of messenger RNA and cellular growth. The translational regulator S6K1 that mTORC1 phosphorylates in coordination with the PDK1 protein kinase appears to be more crucial for growth control (14) . On the other hand, mTORC1 can also phosphorylate and inhibit the eIF4E-binding proteins (4E-BPs), which are a family of negative regulators of eukaryotic translation initiation factor 4E (eIF4E)-dependent translation (15) . Studies implicate both S6K1 and eIF4E in cellular transformation, cell survival, proliferation and motility (16) (17) (18) . mTORC2, on the other hand, is insensitive to nutrient changes and allows cells to grow and survive in nutrient-deprived state (12) . The general view is that mTORC2 regulates AKT signaling to control cellular growth by regulating protein synthesis (19, 20) . As AKT is found to be ubiquitously dysregulated in a variety of cancers (21) (22) (23) , targeting both the mTOR complexes is critical for desired anticancer effects (19) .
Recently, analogs of rapamycin, temsirolimus and everolimus, have been approved by the food and drug authority (FDA) for the treatment of advanced renal cell carcinoma and metastatic breast cancer treatment (24, 25) . These are important indicators suggesting that targeting mTORC1 activity may be beneficial for the management of advanced cancers. However, by not targeting mTORC2 activity, it has been shown that drug resistance quickly develops due to compensatory activation of mTORC2 due to activation of AKT (26) (27) (28) . Therefore, there is a need to develop newer mTOR inhibitors that can inactivate both the mTOR complexes, mTORC1 and mTORC2, for the management of resistant and metastatic cancers.
In this study, we have examined the expression of mTORC1 and mTORC2 in a large cohort of PTC samples and correlated the expression clinical parameters and molecular markers. We have next determined the role of a second-generation mTOR inhibitor, Torin2, that has the ability to inhibit both the activity of mTORC1 and mTORC2 using PTC cell lines in vitro and on nude mice model in vivo.
Materials and methods

Patient selection and tissue microarray construction
Five hundred and thirty-six patients with PTC diagnosed between 1988 and 2004 were selected from King Faisal Specialist Hospital and Research Center. All PTC were analyzed in a tissue microarray (TMA) format. Clinical and histopathological data were available for all the patients. Long-term followup data were available for most of the patients. TMAs were constructed with 2-fold redundancy from formalin-fixed, paraffin-embedded PTC specimens as described previously (29) . Tumor regions were mapped by a pathologist for coring. The TMA was constructed with 0.6 mm diameter cores spaced 0.8 mm apart using a modified tissue microarrayer (Beecher Instruments, Sun Prairie, WI). The TMA block was cut into 5.0 µm sections, adhered to the slide by an adhesive tape-transfer method (Instrumedics, Hackensack, NJ) and UV crosslinked. Abbreviations: mTOR, mammalian target of rapamycin; PARP, poly (ADP ribose) polymerase; PBS, phosphate-buffered saline; PTC, papillary thyroid carcinoma; siRNA, small interfering RNA; TMA, tissue microarray. mTOR signaling in PTC retrieval, Dako Target Retrieval Solution pH 9.0 (Catalog number S2368) was used, and the slides were microwaved at 750 W for 5 min and then at 250 W for 20 min. The Dako Envision Plus System kit was used as the secondary detection system with 3,3'-diaminobenzidine as chromogen. All slides were counterstained with hematoxylin, dehydrated, cleared and mounted. Negative controls included omission of the primary antibody. Only fresh cut slides were stained simultaneously to minimize the influence of slide aging and maximize reproducibility of the experiment. Each TMA spot was assigned an intensity score from 0 to 3 (I 0 , I 1-3 ) and proportion of the tumor staining for that intensity was recorded as 5% increments from a range of 0-100 (P 0 , P 1-3 ). A final H score (range 0-300) was obtained by adding the sum of scores obtained for each intensity and proportion of area stained (H score = I 1 × P 1 + I 2 × P 2 + I 3 × P 3 ).
Using H score and X-tile version 3.6.1 (30) , scoring was done as described previously with a cutoff of 120, 130, 50 and 0 considered as high p-mTOR Ser2481, p-mTOR Ser2448, p-p70S6 and p-4E-BP1 expression, respectively. Other immunohistochemistry markers such as p-AKT Ser473 and PIK3CA (p-110α) were scored as described previously (21, 31) .
Statistical analysis
Contingency table analysis and chi-square tests were used to study the relationship between different variables. Survival curves were generated using the Kaplan-Meier method, with significance evaluated using the Mantel-Cox logrank test. The limit of significance for all analyses was defined as a P-value of 0.05; two-sided tests were used in all calculations. The JMP 9.0 (SAS Institute, Cary, NC) software package was used for data analyses. For in vitro analysis, standard deviation and Student's t-test have been used for statistical purposes.
Cell culture PTC cell line BCPAP was purchased from DSMZ (Braunschh, Germany), and TPC-1 was kindly provided by Dr Bryan McIver (Department of Endocrinology, Mayo Clinic, Rochester, MN) as a gift and cultured as described (32) . Briefly, both cell lines were cultured in RPMI 1640 medium supplemented with 10% (vol/vol) fetal bovine serum, 100 U/ml penicillin and 100 U/ml streptomycin at 37°C in humidified atmosphere containing 5% CO 2 . All in vitro experiments were performed in media supplemented with 5% fetal bovine serum. Both the cell lines were fingerprinted in-house using short tandem repeats PCR and the results were confirmed with published data (33) .
Reagents and antibodies
Torin2 was purchased from Tocris Bioscience (Ellisville, MO). zVADfmk was purchased from Calbiochem (San Diego, CA). Antibodies against p-mTOR (Ser2448), p-mTOR (Ser2481), p-p70S6 kinase (Ser389), p70S6 kinase, p-4E-BP1 (Thr37/46), p-AKT (Ser473), caspase-9, cytochrome c, poly (ADP ribose) polymerase (PARP), caspase-3 and cleaved caspase-3 were purchased from Cell Signaling Technologies (Beverly, MA). Bax clone 6A7 was purchased from Sigma (St Louis, MO). Survivin antibody was purchased from R&D. Beta-actin and XIAP antibodies were purchased from Abcam (Cambridge, UK). Annexin V was purchased from Molecular Probes (Eugene, OR).
Cell lysis and immunoblotting
Cells were treated with indicated doses of Torin2 as described in the legends and lysed as described previously (21) . Immunoblotting was performed with different antibodies and visualized by an enhanced chemiluminescence (Amersham, Arlington HeightsIL) system.
Cell growth studies by MTT assay
Cells (10 4 ) were incubated in triplicate in a 96 well plate in the presence or absence of indicated test doses of Torin2 in a final volume of 0.2 ml for 48 h. The ability of Torin2 to inhibit cell growth was determined by MTT cell viability assays, as described earlier (22) . Replicates of six wells for each dosage including vehicle control were analyzed for each experiment.
Live Dead assay
To measure apoptosis, Live Dead assay (Invitrogen, Eugene, OR) was used as described by the manufacturer. Briefly, 1 × 10 6 cells were treated with indicated doses of Torin2 for 48 h. Following incubation, cells were resuspended in 1 ml phosphate-buffered saline (PBS) containing 50 μM calcein AM and 8 μM ethidium homodimer and cells were incubated in the dark for 20 min. Fifty microliters of suspension was transferred on slides and visualized under an Olympus fluorescent microscope using a long pass filter.
Cell cycle analysis, Annexin V staining and DNA laddering PTC cell lines were treated with different concentrations of Torin2 as described in the legends. For cell cycle analysis, cells were washed once with PBS and resuspended in 500 µl hypotonic staining buffer and analyzed by flow cytometry as described previously (29) . For detection of apoptosis, cells were harvested and percentage apoptosis was measured by flow cytometry after staining with fluorescein-conjugated Annexin V and propidium iodide (Molecular Probes).
Assay for cytochrome c release
Cytochrome c release from mitochondria was assayed as described earlier (21) . Twenty micrograms of proteins from cytosolic and mitochondrial fraction of each samples were analyzed by immunoblotting using an anti-cytochrome c antibody.
Measurement of mitochondrial potential
Cells (1 × 10 6 ) were treated with indicated doses of Torin2 for 48 h. Cells were washed twice with PBS, suspended in mitochondrial incubation buffer (Alexis Corp., Farmingdale, NY). JC1 (5,5′,6,6′-teterachloro-1,1′,3,3′-tetraethylbenzimidazolylcarbocyanine iodide) was added to a final concentration of 10 μM and incubated at 37°C in dark for 30 min. Cells were washed twice with PBS and resuspended in 500 μl of mitochondrial incubation buffer and mitochondrial membrane potential (percentage of green and red aggregates) was measured by flow cytometry as described earlier (21) .
Gene silencing using small interfering RNA mTOR small interfering RNA (siRNA) and scrambled control siRNA were purchased from Cell Signaling Technologies. Cells were transfected using Lipofectamine 2000 (Invitrogen, Carlsbad, CA) for 6 h following which the lipid and siRNA complex was removed and fresh growth medium was added. Cells were lysed 48 h after transfection and specific protein levels were determined by western blot analysis with specific antibodies.
Animals and xenograft study
Six-week-old nude mice were obtained from Jackson Laboratories (Bar Harbor, ME) and maintained in a pathogen-free animal facility for at least 1 week before use. All animal studies were done in accordance with institutional guidelines. For the xenograft study, mice were inoculated subcutaneously into the right abdominal quadrant with 10 million TPC-1 cells in 200 μl PBS. After 1 week, mice were randomly assigned into three groups (n = 5): the first group received 10% dimethyl sulfoxide, and two groups received 2 and 10 mg/kg body weight intraperitoneally. Mice were injected these drugs twice weekly. The body weight and tumor volume of each mouse were monitored weekly. The tumor volume was measured as previously (29) . After 4 weeks of treatment, mice were killed and individual tumors were weighed, and then snap frozen in liquid nitrogen for storage.
Results
Expression/activation of mTORC1 and mTORC2 in PTC samples
We first sought to determine the expression of mTORC1 and mTORC2 using a TMA cohort of 536 PTC samples. Using immunohistochemistry, we initially examined the phosphorylation of mTOR on Ser2448, a marker of mTORC1 activity (34) , as well as the phosphorylation of mTOR on Ser2481, a marker for mTORC2 activity (35) . Constitutive phosphorylation of mTOR at Ser2448 and Ser2481 was observed in 81 and 39% of PTC samples, respectively.
Correlation of mTOR pathway with various clinicopathological features and molecular markers in PTC
Activation of both mTOR proteins was significantly more common in younger age group as shown in Table I and Supplementary Table 2 , available at Carcinogenesis Online. As expected, p-mTORC1 expression was significantly associated with activated 4E-BP1 expression (P = 0.0290) and p-mTORC2 with p-AKT (P = 0.0006) and PIK-3CA (P = 0.0235) ( Figure 1) ; however, p-MTORC2 expression was also found to be associated with activated 4E-BP1 (P = 0.0002) (Supplementary Table 2 , available at Carcinogenesis Online). Similarly, p-70S6 Thr389 expression in PTC significantly correlated with p-AKT (P = 0.0021) and PIK3CA 110 subunit protein (P = 0.0116) (data not shown). Interestingly, coexpression of mTORC2 and mTORC1 activity was seen in a 32.5% (164/504) of the PTC studied and this association was statistically significant (P = 0.0244). Although p-mTORC1 expression showed a significant association with early stage (P = 0.0286), no correlation was observed with gender, histology subtype and extra thyroidal extension (Table I) . Expression of both mTOR proteins did not show any association with disease-free survival.
Taking into consideration, these findings as well as previously reported presence of active mTORC1 and mTORC2 complexes in various cancers (36), we performed functional assays on PTC cell lines using Torin2, a second-generation ATP-competitive inhibitor that is potent and selective for mTOR (37) to determine whether inhibition of mTOR pathways can induced growth inhibition and apoptotic cell death in vitro and in vivo.
Constitutive expression of mTORC1 and mTORC2 complexes and its associated pathways in PTC cell lines
High levels of phosphorylated (activated) mTOR have been reported in a variety of solid tumors (38, 39) . mTOR has also been shown to regulate many molecules that are involved in protein translational pathways such as activation of p706 kinase and 4EBp in many cancer cells (14, 15) . In the next series of experiments, we sought to determine whether functional mTORC1 and mTORC2 are present in PTC cell lines and their inhibition causes inactivation of its associated signaling partners. As shown in Figure 2A , both PTC cell lines showed constitutively activated mTOR at Ser2448 (mTORC1) and treatment of PTC cells with Torin2 blocked mTORC1 activity in a dose-dependent manner. Torin2 treatment also dephosphorylated p70S6 and 4E-BP1 in PTC cells. It has been shown that mTORC1 regulates expression of cyclin D1 via phosphorylation of 4E-BP1 (40) . Therefore, we sought to determine the expression of cyclin D1 following treatment with Torin2. As shown in Figure 2A , expression of cyclin D1 was downregulated in both cell lines following Torin2 treatment suggesting that inactivation of 4E-BP1 also controls expression of cyclin D1 in PTC cells (40) . In addition to activation of mTOR1, Torin2 treatment of PTC cell lines also dephosphorylated mTOR at Ser2481 that is the marker of mTORC2 activity ( Figure 2B ). As AKT activity has been shown to be controlled by mTORC2 activation (19, 20) , we also directly examined the activation of AKT and its downstream target, Bad, in PTC cells following treatment with Torin2. As shown in Figure 2B , there was inactivation of AKT and Bad in PTC cells treated with Torin2. In order to confirm the specificity of Torin2 on activation of mTORC1 and mTORC2 and their downstream targets, we also performed transfection studies with siRNA specifically targeted against mTOR to determine the status of these proteins in PTC cells. BCPAP and TPC-1 cells were transfected with mTOR-specific siRNA and like Torin2, the siRNA-targeting mTOR inactivated p70S6, 4E-BP1, AKT and downregulated expression of cyclin D1 ( Figure 2C ). These data suggest that mTOR regulates the activity of p70S6 leading to inactivation of 4E-BP1 and downregulation of cyclin D1 on one hand and inactivates AKT and its downstream target, Bad, that play a critical role in cell growth and survival.
mTOR kinase inhibition causes inhibition of cell viability and induces apoptosis in PTC cell lines
We next sought to determine whether treatment of PTC cell lines TPC-1 and BCPAP with Torin2 caused inhibition of cell viability. PTC cell lines were treated with various doses ranging from 50 to 800 nM Torin2 for 48 h and cell proliferation was determined by MTT assays. Figure 3A shows that as the dose of Torin2 increased from 50 to 800 nm, cell growth inhibition significantly increased in a dose-dependent manner in both the cell lines. IC 50 was calculated using CalcuSyn software using the above-mentioned doses. As shown in Supplementary Figure 1 , available at Carcinogenesis Online, the IC 50 for BCPAP and TPC-1 cell lines were 347.6 and 380.5 nM, Figure 2D , there was increased apoptosis in cells treated with 200 and 400 nM Torin2 in both the cell lines tested. These data are in concordance with another report that showed that combined inactivation of mTORC1 and mTORC2 leads to apoptosis in thyroid cancer (41) .
Inhibition of mTOR activity in PTC cells induces apoptosis via mitochondrial and caspase-mediated pathway
The first event required for the activation of the mitochondrial apoptotic pathway is inactivation of Bad protein that translocates to mitochondria leading to conformational changes of proapoptotic protein Bax at the amino terminus, exposing the epitope required for homodimerization (42) . Inactivation of Bad secondary to inhibition of mTOR led to activation of Bax protein in BCPAP cell line that was detected using Bax 6A7 antibody that only recognizes N-terminal Bax epitope that is exposed only upon Bax activation (43) . This activation was detected within 4 h after Torin2 treatment and continued up to 16 h ( Figure 4A ). There was also downregulation of Bcl-2 and Bcl-Xl in PTC cells treated with Torin2 (data not shown). We then tested the effect of Torin2 on the mitochondrial membrane potential and release of cytochrome c in these cells. Cells were treated with Torin2 for 48 h and labeled with JC1 dye, and mitochondrial membrane potential was measured by flow cytometry. As shown in Figure 4B , treatment of cells with Torin2 resulted in loss of mitochondrial membrane potential in PTC cells as measured by JC1-stained green fluorescence depicting apoptotic cells. We next sought to determine whether cytochrome c was released from PTC cells after treatment with 200 nm and 400 nM Torin2. Expression of cytochrome c increased in cytosolic fractions treated with Torin2 compared with untreated cells in PTC cells ( Figure 4C ). Finally, we also examined the expression of inhibitors of apoptosis proteins following treatment of PTC cells with Torin2. As shown in Figure 4D , there was downregulation of XIAP, cIAP1 and Survivin in PTC cells treated with Torin2. These data suggest that Torin2 treatment of PTC cell lines leads to activation of the mitochondrial apoptotic pathway. Once cytochrome c is released, it causes activation and cleavage of caspases that leads to apoptosis in cells (21) . We therefore sought to determine whether Torin2-induced release of cytochrome c is capable of activation of caspase-9, caspase-3 and PARP in PTC cells. As shown in Supplementary Figure 2A , available at Carcinogenesis Online, there was activation and cleavage of caspases-9, -3 and PARP following treatment with 200 and 400 nM Torin2 for 48 h in PTC cells. In order to confirm whether Torin2 treatment actually induces apoptosis via activation of caspases, we pretreated PTC cells with 80 µM zVAD-fmk, a universal inhibitor of caspases for 2 h followed by treatment with 400 nM for 48 h. As shown in Supplementary Figure 2B , available at Carcinogenesis Online, there was activation and cleavage of caspase-3 and PARP in cells treated with Torin2; however, pretreatment of PTC cells with zVAD-fmk inhibited Torin2-induced activation and cleavage of caspase-3 and PARP. We also found that pretreatment of PTC cells with zVAD-fmk inhibited Torin2-induced apoptosis (Supplementary Figure 2C and D, available at Carcinogenesis Online) clearly indicating that Torin2-induced apoptosis is caspase dependent.
Torin2-mediated inhibition of mTOR activation suppresses PTC tumorigenesis in nude mice xenograft
Our in vitro data showed that Torin2 treatment had the ability to prevent phosphorylation of p70S6, 4E-BP1, AKT and downregulated expression of cyclin D1 in PTC cells. In addition, our in vitro data also showed that treatment of PTC cells with Torin2 induced caspase-dependent apoptosis via the mitochondrial apoptotic pathway. These data imply that targeting the mTOR pathway in PTC cells may be beneficial as a therapeutic modality. Therefore, we expanded our study to nude mice xenograft of PTC cells followed by treatment with Torin2 to determine the effect of mTOR inhibition on tumor growth and volume. Nude mice were inoculated subcutaneously in the right abdominal quadrant with 10 million TPC-1 cells. Mice were then treated with either two doses of Torin2 in treatment group (2 and 10 mg/kg/dose), or vehicle dimethyl sulfoxide-treated control groups (n = 5). After 4 weeks of treatment, mice were killed and tumors were collected. As shown in Figure 5A , Torin2 treatment causes a timedependent regression of TPC-1 xenograft tumors in mice compared with vehicle-treated mice that reached significance (P < 0.0500) at the end of fourth week of treatment at the dose of 10 mg/kg/dose Torin2. A significant reduction in tumor weight ( Figure 5B ) was also observed at this treatment condition. Additionally, images of tumor after necropsy showed that Torin2 treatment resulted in shrinkage of tumor size with minimal necrosis ( Figure 5C ). Finally, proteins extracted from tumors post-necropsy were immunoblotted with antibodies against mTOR phosphorylated at Ser2448 and Ser2481, p-4E-BP1, p-AKT, cyclin D1, Bcl-Xl and caspase-3. As shown in Figure 5D , decrease in tumor volume and size was due to inactivation of mTOR, AKT, 4E-BP1 and downregulation of expression of cyclin D1 and Bcl-Xl. Reduction of tumor size also correlated with activation of caspase-3. These data suggest that Torin2 is also effective against PTC xenograft in shrinking the tumor size via inhibition of mTOR-dependent pathways and induction of caspase-mediated apoptosis.
Discussion
The mTOR protein is a serine/threonine kinase that forms two functionally unique complexes: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). mTORC1 function is mediated After treatment, cells were lysed and immunoblotted with antibodies against p-mTOR (Ser2481), p-AKT (Ser473) and p-Bad. Beta-actin was used for equal loading. (C) BCPAP cells were transfected with scrambled siRNA (100 nM) and mTOR siRNA (50 and 100 nM) with Lipofectamine as described in Materials and methods. After 48 h of transfection, cells were lysed and equal amounts of proteins were separated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis, transferred to immobilon membrane and immunoblotted with antibodies against mTOR, p-p70S6, p-4E-BP1, cyclin D1, p-AKT and beta-actin as indicated. mTOR signaling in PTC through phosphorylation of S6K1 and 4E-BP1, which stimulate messenger RNA translation and growth (14, 15) , whereas mTORC2 has been shown to phosphorylate a very important member of the PI3-kinase pathway, AKT (19, 20) . Our clinical data showed that both the complexes of mTOR, mTORC1 and mTORC2, were activated in 81 and 39% of PTC samples, respectively. This is in agreement to an earlier pilot study that has investigated the mTOR pathway in a small cohort of 30 thyroid cancers and reported mTORC1 expression in 100% of the PTC histology subtype samples studied (44) . In addition, we also found that mTORC1 was significantly associated with mTORC2 and 4E-BP1 and mTORC2 was associated with activated AKT. Our data also found a significant association between high expression of P70S6 and BRAF-mutated PTC (P = 0.0080) compared with PTC with wild-type BRAF, which is in concordance with a previous study reported by Faustino et al. (45) . However, unlike Faustino et al. study, we did not find any association with activated mTOR (2448) in BRAF mutated PTC samples (unpublished data).
The United States Food and Drug Administration approved two mTOR inhibitors, temsirolimus and everolimus, for the treatment of renal cell carcinoma, which have shown promising results (19) . However, recent studies have shown that these results are short lasting and do not cure the disease (26, 27, 46) . One major problem with these FDA-approved drugs is that their target was mTORC1 only and not mTORC2 and therefore resistance quickly developed against these agents. The presence of coexpression both the complexes of mTOR in our cohort of clinical samples clearly indicates the importance of targeting both the mTOR complexes simultaneously to avoid resistance to therapy. Therefore, in this study, we have examined in detail the role of Torin2, a second-generation selective inhibitor of mTOR complexes that has been shown to be effective against activation of mTORC1 and mTORC2 on PTC cell lines and PTC xenograft model. We found that Torin2 inactivated mTORC1 and mTORC2 at dose of 400 nM in both the cell lines used. Not only did the activity of mTORC1 and mTORC2 decreased, the downstream targets of mTOR complexes, P70S6, 4E-BP1 and AKT, were also inactivated following Torin2 treatment. 4E-BP1 and P70S6, once phosphorylated, lead to formation of the eIF4F translation initiation complex (47) that is necessary for the maintenance of malignant phenotype of cancer cells (48) . In addition, 4E-BP1 overexpression is also associated with a poor survival in melanoma (49) and controls the expression of cell cycle regulator, cyclin D1 (40) . Therefore, by inactivating 4E-BP1, the ElF4F complex fails to develop and cells are allowed to go into a cell cycle arrest due to downregulation of cyclin D1.
Interestingly, Torin2 treatment of PTC cells also inactivated an important survival molecule, AKT, that has been shown to play a major role in cell survival, growth of malignant cells (50) and has been found to promote a poor survival in various cancers (21, 23) . By inactivating AKT, the downstream target of AKT Bad, a proapoptotic member of the Bcl-2 family, is also dephosphorylated. Native Bad interacts with antiapoptotic proteins, Bcl-2 and Bcl-Xl negating their effect thereby allowing Bax to exert its proapoptotic action at the level of mitochondria (42) . Our data indicate that Torin2 treatment causes activation of Bax protein, probably leading to conformational changes of the protein thereby allowing the membrane potential of mitochondria to change leading to release of cytochrome c into the cytosole.
For efficient apoptosis to occur, the mitochondrial apoptotic pathway needs to be activated for the caspases to exert their proapoptotic effects. However, inhibition of the inhibitors of apoptosis is also necessary for this pathway to be completely active. Torin2 treatment downregulates the expression of key members of the inhibitor of apoptosis family, XIAP, cIAP1 and Survivin, indicating the effectiveness of this inhibitor in successfully activating the apoptotic machinery. Caspases are the final effectors of both extrinsic and intrinsic apoptotic pathway and are present as inactive zymogens that need to be activated and cleaved to exert their apoptotic function (51) . In our study, we found that Torin2 treatment activates and cleaves caspases-9 and caspase-3 via activation of the mitochondrial apoptotic pathway leading to efficient apoptosis in PTC cells thereby highlighting the importance of Torin2 in the management of PTC.
Our in vitro data were validated by in vivo studies where PTC xenografts treated with Torin2 showed regression of tumor size and volume secondary to inactivation of mTORC1 and mTORC2. In addition, we also detected inactivation of downstream targets of mTOR complexes, 4E-BP1 and AKT, as well as downregulation of indirect targets such as cyclin D1, Bcl-Xl and caspase-3. These findings clearly indicate the effectiveness of Torin2 in successfully inactivating the mTOR complexes leading to regression of PTC xenografts in vivo.
In summary, our clinical data provide ample evidence that mTOR1 and mTOR2 complexes are active in a significant number of PTC samples. Our in vitro data showed that inhibition of mTORC1 and mTORC2 activity by Torin2, a second-generation mTOR inhibitor, can induce mitochondrial-mediated apoptosis in PTC cells. Finally, Torin2-mediated anticancer effects were seen in PTC generated xenografts in mice via inhibition of mTORC1 and mTORC2 activity. These Whole-cell homogenates from mice treated with vehicle, and two doses of Torin2 were immunoblotted with antibodies against mTOR phosphorylated at Ser2448 and 2481, p4E-BP1, pAKT, cyclin D1, Bcl-Xl and caspase-3. Beta-actin was used as a control for equal loading.
